Standout Papers

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes 2007 2026 2013 2019 4.3k
  1. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (2007)
    Stephen D. Wiviott, Eugene Braunwald et al. New England Journal of Medicine
  2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2018)
    Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine
  3. Standardized Bleeding Definitions for Cardiovascular Clinical Trials (2011)
    Roxana Mehran, Sunil V. Rao et al. Circulation
  4. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (2013)
    Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine
  5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2018)
    Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet
  6. Cytochrome P-450 Polymorphisms and Response to Clopidogrel (2008)
    Jessica L. Mega, Sandra Close et al. New England Journal of Medicine
  7. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome (2011)
    Jessica L. Mega, Eugene Braunwald et al. New England Journal of Medicine
  8. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events (2015)
    Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine
  9. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004)
    James A. de Lemos, Michael A. Blazing et al. JAMA
  10. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial (2009)
    Gilles Montalescot, Stephen D. Wiviott et al. The Lancet
  11. Vorapaxar in the Secondary Prevention of Atherothrombotic Events (2012)
    David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine
  12. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention (2007)
    Stephen D. Wiviott, Dietmar Trenk et al. Circulation
  13. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus (2019)
    Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation
  14. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (2008)
    Stephen D. Wiviott, Eugene Braunwald et al. Circulation
  15. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials (2009)
    Michelle L. O’Donoghue, Eugene Braunwald et al. The Lancet
  16. Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel (2009)
    Jessica L. Mega, Sandra Close et al. Circulation
  17. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis (2010)
    Jessica L. Mega, Sandra Close et al. The Lancet
  18. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial (2017)
    Marc S. Sabatine, Lawrence A. Leiter et al. The Lancet Diabetes & Endocrinology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 193 standout
Sub-graph 1 of 13

Citing Papers

Reteplase versus Alteplase for Acute Ischemic Stroke
2024 Standout
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
2024 Standout
2 intermediate papers

Works of Stephen D. Wiviott being referenced

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes
2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Stephen D. Wiviott 21684 15064 10804 200 33.8k
Sabina A. Murphy 29083 17306 7761 482 42.0k
A. Michael Lincoff 20305 13664 4272 409 30.0k
Kenneth W. Mahaffey 31634 12747 10886 646 46.4k
Marc S. Sabatine 27026 22026 12790 499 49.0k
Benjamin M. Scirica 12228 6415 5590 268 18.5k
Colin Baigent 8741 10882 4631 135 22.1k
Carolyn H. McCabe 29028 16991 2840 181 37.7k
Robert P. Giugliano 17451 13091 3681 544 29.3k
Gilles Montalescot 22451 12008 2030 546 27.9k
Dominick J. Angiolillo 20084 11580 2819 589 23.7k

All Works

Loading papers...

Rankless by CCL
2026